Trevi Therapeutics, Inc. (TRVI) Earnings Call Transcript & Summary
March 25, 2021
Earnings Call Speaker Segments
Jennifer Good
executiveThanks for being here this afternoon, everybody, for our discussion of Trevi's 2020 fourth-quarter and full-year numbers. Joining me are Dr. Bill Forbes, our Chief Development Officer, and Chris Seiter, who holds the CFO role at Trevi. Bill joined the company as February began, and he brings a well-proven record of success in creating drugs and obtaining regulatory clearances. During his time with Salix, Bill led programs that won approval for 12 NDAs. We're delighted to have Bill on the Trevi roster, and after our prepared comments conclude, he'll take part in Q&A. Everyone faced numerous challenges in 2020, yet at Trevi we remained focused on advancing enrollment in our clinical trials. Our team is motivated to achieve data readouts for the two main indications we're pursuing—pruritus and cough—because we believe Haduvio's broad mechanism of action may apply to multiple other related conditions. The primary indications we're targeting are severe pruritus associated with prurigo nodularis and chronic cough linked to idiopathic pulmonary fibrosis, both of which are serious conditions that cause significant quality-of-life burdens for patients. From our perspective, these illnesses involve shared pathophysiology through the mu and kappa receptors, working both centrally and peripherally. Our most advanced clinical program is in pruritus. Prurigo nodularis, which we refer to as PN, is a severe and debilitating skin condition characterized by nodules and papules on the skin, accompanied by unrelenting, intense itching. At present, there are no approved treatments for this indication. PN is a chronic illness. Because of continual scratching, the papules and nodules multiply and progressively worsen. We put the worldwide prevalence of PN at approximately 730,000 patients — 300,000 in the United States and 430,000 elsewhere around the globe. We are right now running a Phase IIb/III study in this condition, known as our PRISM trial. Enrollment for the PRISM trial is underway in the U.S. plus Europe. And as of right now, over sixty locations have been brought online. The study's main goal involves a responder analysis, which looks at decreases in itch severity measured through the Worst Itch Numerical Rating Scale following twelve weeks of blinded fixed dosing. At this point, we've randomized about 240 out of the 360 subjects we plan to enroll in the trial. On an encouraging note, nearly every subject who has completed the blinded dosing phase has opted to continue into the open-label extension part of the study, which lets us gather long-term safety and efficacy information on these individuals. Enrollment in this trial was adversely affected by COVID-19 between December 2020 and the middle of February 2021. You probably caught this in the headlines, but a lot of Europe went back into lockdown over that period. Meanwhile, on the American side, a great number of individuals remained at home as a result of the very elevated COVID case counts nationwide. Enrollment started to recover beginning in the middle of February. March has proven to be a strong month up to this point, and we believe we're positioned to continue gaining momentum in this study. With that said, I want to acknowledge how tough the past few months have been given the impact of COVID-19, and we realize this will continue to act as a sort of headwind that we'll have to keep handling until the study wraps up. Even so, given what the sites are telling us and the healthy level of activity in March, we remain confident that enrollment can wrap up in Q3 of this year, with top line data reported by the end of the year. On top of that, we're still taking part in a range of virtual dermatology conferences. During the middle of March, 4 abstracts/posters of ours got accepted. Among them was a talk on how mu and kappa opioid receptors function in pruritus, plus posters covering the Phase II — the Phase II clinical data in pruritus as well as PN and uremic pruritus, which offer clinical evidence that nalbuphine ER could matter for treating chronic pruritus across a wide variety of conditions. Additionally, we intend to take part in the American Academy of Dermatology VMX this April and the European Academy of Dermatology and Venereology Spring Symposium this May. Abstracts have been submitted for both, and we're now awaiting word on acceptance. Let me move to our second clinical program, which covers chronic cough and idiopathic pulmonary fibrosis, or IPF. IPF is a severe, progressive illness characterized by scarring in the lung tissues. Among the most debilitating symptoms patients face with this disease is chronic coughing, affecting roughly 70% to 85% of them, and no approved therapies exist for it. Worldwide prevalence of IPF is estimated at more than 1 million patients. Within the U.S., our estimate is around 130,000 IPF patients, with a matching figure for Europe. Because IPF carries a high 5-year mortality rate, both prescribers and patients want not just to slow disease progression but also to see quality of life improve. For patients dealing with this disease, cough ranks among the most troublesome symptoms. Our study is a Phase II crossover design, double-blind, with a washout lasting 14 days between every 3-week treatment period. The main measure we're assessing is the primary percent change in daytime cough frequency relative to baseline. To capture daytime cough frequency, a digital cough monitor is used, and results from the treatment arm are compared against placebo. This trial is currently running in the U.K. Given that this patient population is considered high risk for COVID due to compromised lung function, COVID-19 restrictions have impacted this trial more severely than our PN study. Over the late summer, enrollment began recovering, but the U.K. shut things down once more in early December and handed this patient population a shelter-in-place directive. Because of those restrictions, new subject enrollment was halted once again. So we're aware that those limitations are going to start being eased at the close of this month, and our expectation is that the trial will get back to enrolling patients in the U.K. during the second quarter of 2021. On top of that, Trevi is pursuing approvals from regulators and an ethics Board so that we can add sites for the study in Germany. What we're aiming for is the possibility of speeding up enrollment and lowering the danger that comes with recruiting in just one country while the pandemic is going on; so to wrap up, our attention is on finishing enrollment across both clinical trials within this year and getting the data reported. Both of these are serious conditions, and there are no approved therapies for them, and the stories patients tell us about how much these diseases disrupt their lives are what drive us. At this point I'm going to pass things to Chris Seiter, the Chief Financial Officer of Trevi, so he can give you a financial update. However, before doing so, you might have noticed the 8-K that we filed this week, which says Chris is going to depart Trevi in April. Before he became a CFO, Chris worked for over 20 years as an investment banker; so he's made the decision to take an interesting opportunity with a biotech fund, where he'll put to use the skills he gained in banking as well as in operations. He will certainly be missed by us, but I'm wishing him the best in his next opportunity. So with that, Chris, I'll pass it to you for your final earnings report for Trevi.
Chris Seiter
executiveOkay, thanks, Jennifer. Just a quick note that you can find the complete financial results for Q4 2020 and the entire year in the press release we put out before this call, as well as in our 10-K filed with the SEC. Looking at the fourth quarter of 2020, our net loss came in at $9.5 million, versus a net loss of $6.5 million during the same quarter in 2019. R&D expenses totaled $6.6 million in Q4 2020, up from $4.8 million in the comparable period of 2019. That rise was mainly driven by more activity in our Phase IIb/III PRISM trial, along with higher costs for buying clinical trial supplies. G&A expenses reached $2.6 million in the fourth quarter of 2020, compared with $1.9 million in the same period of 2019. This increase largely reflects greater stock-based compensation expenses and higher consulting fees. Now let's look at the full year. For the year that ended December 31, 2020, our net loss was $32.8 million, compared to a net loss of $26.1 million in 2019. R&D expenses came to $22.3 million for the full year 2020, versus $19.3 million in 2019. The growth was primarily attributable to increased activity in our Phase IIb/III PRISM trial, as well as higher expenses tied to purchasing clinical trial supplies. G&A expenses were $10.2 million for the full year 2020, compared to $7.3 million in 2019. This rise is mainly due to greater stock-based compensation expenses, higher consulting fees, and increased costs associated with being a public company. As of December 31, 2020, our cash and cash equivalents stood at $45 million, compared to $57.3 million as of December 31, 2019. After 2020 ended, we sold roughly $4.4 million of our common stock through our ATM facility. We expect our current cash position will be enough to fund operations into the second quarter of 2022, beyond the anticipated top line results from the PRISM trial, which we expect in the fourth quarter of 2021. That wraps up our prepared remarks; I'll now hand the call back to the operator for Q&A.
Gary Nachman
analystTo start, Chris, my best wishes to you, and Bill, welcome aboard at Trevi. So a few things regarding PRISM. Do you anticipate needing any extra sites to finish the trial during the third quarter, considering the COVID headwinds? And Jen, I'm not sure whether you'd like to give that exact figure, where things stand at the moment. Then a follow-up. What have discontinuation rates looked like? Is there anything unusual you're observing? And how do the AEs appear thus far, I suppose, broadly throughout the whole study?
Jennifer Good
executiveYes. Thanks, Gary. I'll go ahead and let Bill answer that since he's sort of fully at the helm here of the study. Go ahead, Bill.
Bill Forbes
executiveGary, let me share a few thoughts with you. What we expected to come up first, I think, was people asking how sure we are that we can meet these timelines. For the PRISM trial, there are several things we're monitoring. We do sense that the COVID situation may be easing somewhat. In Germany specifically, where our PRISM study is running, enrollment is going well; Germany has been something we've watched closely since there was discussion of possible renewed shutdowns, so when it comes to these centers and COVID, we're cautiously optimistic. Over the past month, as Jennifer noted in her remarks, we've observed solid activity. As for competition among the centers, we believe we're positioned well. It appears certain competitors might be pulling out, while others are perhaps moving slowly, at least right now, when it comes to getting started. So we believe our centers are mainly focused on our PRISM study. On the operational side, we remain concentrated on whatever resources and support we're able to give our investigators. And regarding the investigators and coordinators, they're quite confident they can meet the timelines we've set out for them. Related to what you asked is whether we'll bring on additional centers. Yes, we will; right now we're in the process of adding a handful of high-quality centers — not many, only a few. At this late stage of the PRISM study, we've been extremely careful about whom we bring in, and during selection we press them hard to confirm they believe they can make a contribution within the time window remaining. You also raised study disposition matters. I won't comment on study disposition. I will say that with respect to adverse events, the ones we've previously observed are largely identical to those appearing in the studies currently underway. Nausea, headache, dizziness, somnolence — those sorts of adverse events we know are tied to nalbuphine are what we keep seeing.
Gary Nachman
analystAll right, and let me just fit in one more quickly. Jennifer, I want to confirm I heard you correctly — regarding chronic cough, do you still believe that data can be available before the year is over, even with all the difficulties there?
Jennifer Good
executiveThat's right. Good question, Gary. As you likely recall, we withdrew our formal guidance once COVID arrived. We haven't really restored it officially since then, because honestly, at no point have we felt we'd truly gotten past that stage. Within the company, we're aiming to have this fully enrolled by the close of the year. It isn't a large trial. It involves as many as 60 patients, with 44 completing, so we'll find out; we'll continue to keep you posted on that. We didn't really reissue formal guidance, but internally we're working hard to finish that by the end of the year.
Annabel Samimy
analystCongrats on the new role, Chris. I've just got a couple of quick questions. First, on the — I realize you didn't provide much detail about the rate at which patients are discontinuing. But the approaches you've implemented to address that rate, are they at least performing as you anticipated? And have you managed to keep patients on therapy the way you'd hoped? Then, regarding those patients who move to OLE, what's the maximum amount of time any patient has received treatment within that study? And separately, for IPF, is there any consideration of adding sites beyond Europe? Right now Europe seems quite challenging given the lockdowns and restrictions. Any consideration of moving it to the U.S., where conditions are somewhat more open? A few IPF — several additional IPF trials have halted or been discontinued, so perhaps there's greater availability here.
Jennifer Good
executiveI'll take this one, and feel free to chime in afterward — at the end, if you'd like. So Annabel, as you're aware, we discussed early on that — there are a number of mechanisms incorporated into this for handling discontinuations, which essentially relate to education at the site and at the patient level. If issues arise — early on here, we'll kind of check back in on things. I'd say all of those are up and running and seem to be effective. I mean the tough part, and I believe the reason Bill prefers not to make any comments, is that in a blinded study it's genuinely difficult to know what's happening; but yes, nothing there is excessively concerning. I think it's something we must always handle. But yes, the approach — I believe the measures we've implemented appear to be effective. Regarding open label, I think your question was about the maximum duration we've observed for patients. We have many patients, more than 50, who have completed a year of treatment; so Bill has done a great job establishing our safety database. There's substantial efficacy data there. I think one of Bill's priorities is to get in and begin sort of extracting insights from that open-label data, but we've achieved really strong results with the transition into the open label and with patients staying on through that part of the study; and concerning shifting IPF into the U.S., we chose the U.K. because there's excellent expertise there. I believe that remains true, so we haven't examined that so far. I think we believe we can accomplish it in Europe, and that's still the plan to try to carry that through. Bill, anything you'd like to add to what I've said?
Bill Forbes
executiveNo, I believe you've addressed everything. Clearly, when we consider the titration phase, and referring back to what Jennifer mentioned, it remains blinded. It's genuinely difficult to determine how these patients are allocated across the treatment arms. Still, at this moment, we feel encouraged by how patients are advancing through the double-blind portion. Once you move into the open-label part, and I've had the opportunity to examine that data more carefully, that is quite encouraging too. So, in a blinded trial, making statements is obviously challenging. Yet overall, I'd say this is performing in the manner we anticipated.
Serge Belanger
analystI've got a couple of things to ask, and they're about PRISM. First off, congratulations and best wishes to Chris on the new role. Regarding the PRISM trial, when we last talked, I believe you mentioned keeping enrollment at a rate of 20 to 30 patients each month; it seems that slowed down over the holidays and toward the end of the year because of COVID, but do you believe you can return to that pace by March and beyond? Then my second question. Given the delays with the IPF trial, does that alter your view of the LID program and whether you'd consider moving it ahead?
Jennifer Good
executiveYes. I'll have Bill address enrollment for sure. I'd simply note that 120 subjects remain; so reaching that by Q3 means about 20 or so across the coming 6 months. So I'll let Bill speak to that. But Bill, allow me to finish on the LID, then I'll hand it to you; so Serge, as we've discussed previously, we really — when COVID struck especially, we decided here that we would focus hard on our 2 lead programs and reach data on them. We remain quite interested in the LID program and have completed solid work preparing for a Phase II program. A protocol has been written; a CRO has been chosen, yet we won't start that study until we actually see data from both of these studies. So we're still quite interested, but we want to reach data on both programs. I think largely because, well, you can grasp the reasoning. We want to essentially chase the best optionality. Should the data be strong in PN, we want to ensure whatever we add as another indication fits with PN. Should the data be extremely strong in IPF cost, we might want to examine other cost indications; so all of that will be weighed against one another. So we'll hold off until we have that. We know what we've got, and then we'll make those calls. Bill, I'll let you just address enrollment and numbers and what you believe we can accomplish.
Bill Forbes
executiveYeah. No. Serge, I believe your point is accurate — we're seeing somewhere between 20 and 30 each month. With February now behind us and March having looked like a really robust month for us, our confidence is high at the moment. Should that pace carry on from here — and that's the reason behind a few remarks I offered regarding how we view things more broadly with PRISM when Gary raised his question earlier on this call — then I'd say the kind of figures we're aiming for fall in that 20 to 30 band. Clearly, our hope is to do better than that and keep pushing ahead. That said, we're staying careful here. As I mentioned, we're examining several factors. Looking at COVID, like I said, it appears to be letting up. That's definitely providing meaningful help. Combined with everything we're rolling out across the centers plus bringing on a handful of additional centers, I believe we can get there.
Jennifer Good
executiveEveryone, we appreciate you joining us on today’s call. Our gratitude also goes out to the Trevi team, the investigators involved in our studies, and each participant who keeps taking part in our clinical trials throughout this difficult period; we’re eager for ongoing advances and to bring you another update in May. Thank you.
Operator
operatorAppreciate everyone joining us on this call, and that wraps up what we had scheduled for today. You're free to drop off now. Have a wonderful rest of your day, everybody.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Trevi Therapeutics, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Trevi Therapeutics, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Trevi Therapeutics, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.